YD Bio (YDES) Accumulated Expenses (2024 - 2025)
YD Bio's (YDES) quarterly Accumulated Expenses came in at $437.9 billion in Q4 2025, up 140.11% year-on-year from $182.4 billion in Q4 2024, and up 69197955.51% on a QoQ basis from $632762.0 in Q2 2025.
YD Bio (YDES) Accumulated Expenses (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Accumulated Expenses data on file, last reported at $437.9 billion in Q4 2025.
- On a quarterly basis, Accumulated Expenses rose 140.11% year-over-year to $437.9 billion in Q4 2025; TTM through Dec 2025 was $437.9 billion, a 140.11% increase from a year earlier, with the FY2025 full-year figure at $437.9 billion, up 140.11% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $437.9 billion, up from $632762.0 in the prior quarter.
- Over the last five years, Accumulated Expenses for YDES reached as high as $437.9 billion in Q4 2025 and fell as low as $632762.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 437.86 Bn |
| Jun 30, 2025 | 632,762.00 |
| Dec 31, 2024 | 182.36 Bn |